Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.63 |
| ▸ | EGFR | P00533 | 2/20 | 0.61 |
| ▸ | GAK | O14976 | 1/20 | 0.61 |
| ▸ | FLT1 | P17948 | 4/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.61 |
| ▸ | FLT4 | P35916 | 2/20 | 0.61 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.59 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.59 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.59 |
| ▸ | FBP1 | P09467 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650787 | 0.87 | FBP1 (0.66) | KDREGFRGAKFLT1FGFR1 | |
| SCHEMBL5652844 | 0.80 | EGFR (0.66) | KDREGFRGAKFLT1FGFR1 | |
| SCHEMBL5647913 | 0.80 | EGFR (0.66) | KDREGFRGAKFLT1FGFR1 | |
| SCHEMBL5648407 | 0.79 | EGFR (0.65) | KDREGFRGAKFLT1FGFR1 | |
| SCHEMBL5651406 | 0.78 | EGFR (0.71) | KDREGFRGAKFLT1FGFR1 | |
| SCHEMBL5652670 | 0.77 | KDR (1.00) | KDR | |
| SCHEMBL7865988 | 0.77 | KDR (0.80) | KDREGFRFLT1FGFR1FLT4 | |
| SCHEMBL5958924 | 0.77 | KDR (0.83) | KDREGFRGAKFLT1FGFR1 | |
| SCHEMBL7864780 | 0.77 | KDR (0.83) | KDREGFRGAKFLT1FGFR1 | |
| SCHEMBL6911101 | 0.76 | TNNI3K (0.59) | KDREGFRFLT1FGFR1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2005115145-A2 | QUINONE SUBSTITUTED QUINAZOLINE AND QUINOLINE KINASE INHIBITORS | WYETH (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | KDR, FLT1, FLT4 | KDR 1/4885EGFR 439/4885GAK 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.